Preclinical Data Supports Gamgertamig as BCMA×CD3 T-cell Engager for B-cell Malignancies
Gamgertamig, BCMA×CD3 bispecific T-cell engager, has demonstrated potent cytotoxicity and broad B-cell depletion in preclinical models, with a >50-fold affinity bias toward BCMA.